KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Idexx Laboratories (IDXX) EBIAT (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of EBIAT data on record, last reported at $248.2 million in Q4 2025.

  • For Q4 2025, EBIAT rose 14.82% year-over-year to $248.2 million; the TTM value through Dec 2025 reached $1.1 billion, up 19.33%, while the annual FY2025 figure was $1.1 billion, 19.33% up from the prior year.
  • EBIAT reached $248.2 million in Q4 2025 per IDXX's latest filing, down from $274.6 million in the prior quarter.
  • Across five years, EBIAT topped out at $294.0 million in Q2 2025 and bottomed at $132.0 million in Q2 2022.
  • Average EBIAT over 5 years is $210.8 million, with a median of $208.3 million recorded in 2021.
  • Peak YoY movement for EBIAT: skyrocketed 82.64% in 2021, then tumbled 34.86% in 2022.
  • A 5-year view of EBIAT shows it stood at $162.7 million in 2021, then rose by 5.83% to $172.2 million in 2022, then rose by 12.96% to $194.5 million in 2023, then increased by 11.12% to $216.1 million in 2024, then rose by 14.82% to $248.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $248.2 million in Q4 2025, $274.6 million in Q3 2025, and $294.0 million in Q2 2025.